Skip to main content

Advertisement

SpringerLink
Log in

Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases

  • Systemic Therapies in Colorectal Cancer (SM Kazmi, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Purpose of Review

This review provides an overview of the current role of biologics, anti-vascular endothelial growth factor (VEGF) inhibitors and anti-epidermal growth factor receptor (EGFR) inhibitors, in the perioperative treatment of colorectal liver metastases as well as a discussion of their future trends.

Recent Findings

Over the past decade, a number of clinical trials have suggested that the use of biologics with cytotoxic agents may increase median overall survival in certain subsets of patients with colorectal liver metastases. The benefit of these agents is limited to borderline resectable and unresectable hepatic metastases and is not seen in upfront resectable disease. In the RAS wild-type population, the difference in efficacy of VEGF and EGFR inhibitors in combination with chemotherapy is minimal. These agents perform differently depending on primary tumor location; bevacizumab has greater efficacy in right-sided tumors, whereas cetuximab has greater efficacy in left-sided tumors. While biologics benefit patients in the neoadjuvant setting, studies have not shown similar results in the adjuvant setting.

Summary

Given the variability of patient presentations as well as the risk of treatment-related toxicity, the addition of biologics requires careful consideration of patient’s medical fitness, surgical risk, and tumor profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9. https://doi.org/10.1097/01.sla.0000217629.94941.cf.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810. https://doi.org/10.1186/1471-2407-14-810.

    Article  PubMed  Google Scholar 

  3. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80. https://doi.org/10.1200/JCO.2007.11.0833.

    Article  PubMed  Google Scholar 

  4. House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52, 52-5. https://doi.org/10.1016/j.jamcollsurg.2009.12.040.

    Article  PubMed  Google Scholar 

  5. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73(9):727–31. https://doi.org/10.1002/bjs.1800730917.

    Article  CAS  PubMed  Google Scholar 

  6. Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15(2):91–103. https://doi.org/10.1111/j.1477-2574.2012.00557.x.

    Article  PubMed Central  Google Scholar 

  7. Nagano Y, Nojiri K, Matsuo K, Tanaka K, Togo S, Ike H, et al. The impact of advanced age on hepatic resection of colorectal liver metastases. J Am Coll Surg. 2005;201(4):511–6. https://doi.org/10.1016/j.jamcollsurg.2005.05.010.

    Article  PubMed  Google Scholar 

  8. Langella S, Russolillo N, Forchino F, Lo Tesoriere R, D'Eletto M, Ferrero A. Impact of obesity on postoperative outcome of hepatic resection for colorectal metastases. Surgery. 2015;158(6):1521–9. https://doi.org/10.1016/j.surg.2015.07.024.

    Article  PubMed  Google Scholar 

  9. Elias DM, Ouellet JF. Incidence, distribution, and significance of hilar lymph node metastases in hepatic colorectal metastases. Surg Oncol Clin N Am. 2003;12(1):221–9. https://doi.org/10.1016/s1055-3207(02)00080-7.

    Article  PubMed  Google Scholar 

  10. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51. https://doi.org/10.1200/JCO.2008.17.5299.

    Article  PubMed  Google Scholar 

  11. Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8. https://doi.org/10.1016/j.suronc.2018.05.012.

    Article  PubMed  Google Scholar 

  12. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127(5):512–9. https://doi.org/10.1067/msy.2000.105294.

    Article  CAS  PubMed  Google Scholar 

  13. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94(11):1386–94. https://doi.org/10.1002/bjs.5836.

    Article  CAS  PubMed  Google Scholar 

  14. Bredt LC, Rachid AF. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2014;12:391. https://doi.org/10.1186/1477-7819-12-391.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. https://doi.org/10.1016/S1470-2045(13)70447-9.

    Article  CAS  PubMed  Google Scholar 

  16. Khoo E, O'Neill S, Brown E, Wigmore SJ, Harrison EM. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford). 2016;18(6):485–93. https://doi.org/10.1016/j.hpb.2016.03.001.

    Article  Google Scholar 

  17. Araujo RL, Gonen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(9):3070–8. https://doi.org/10.1245/s10434-014-4354-6.

    Article  PubMed  Google Scholar 

  18. Wang ZM, Chen YY, Chen FF, Wang SY, Xiong B. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41(9):1197–203. https://doi.org/10.1016/j.ejso.2015.05.020.

    Article  PubMed  Google Scholar 

  19. Goere D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686–91. https://doi.org/10.1097/SLA.0b013e3181d35983.

    Article  PubMed  Google Scholar 

  20. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71. https://doi.org/10.1200/JCO.2008.20.1301.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224(4):509–20; discussion 20-2. https://doi.org/10.1097/00000658-199610000-00009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6. https://doi.org/10.1200/JCO.2006.09.0928.

    Article  CAS  PubMed  Google Scholar 

  23. Maeda Y, Shinohara T, Nagatsu A, Futakawa N, Hamada T. Long-term outcomes of conversion hepatectomy for initially unresectable colorectal liver metastases. Ann Surg Oncol. 2016;23(Suppl 2):S242–8. https://doi.org/10.1245/s10434-015-4460-0.

    Article  PubMed  Google Scholar 

  24. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72. https://doi.org/10.1200/JCO.2005.05.3074.

    Article  CAS  PubMed  Google Scholar 

  25. Zhao J, van Mierlo KMC, Gomez-Ramirez J, Kim H, Pilgrim CHC, Pessaux P, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104(8):990–1002. https://doi.org/10.1002/bjs.10572.

    Article  CAS  PubMed  Google Scholar 

  26. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009;14(11):1095–105. https://doi.org/10.1634/theoncologist.2009-0152.

    Article  PubMed  Google Scholar 

  27. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83. https://doi.org/10.1200/JCO.2008.20.5278.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. https://doi.org/10.1056/NEJMoa032691.

    Article  CAS  PubMed  Google Scholar 

  29. Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108(8):1566–70. https://doi.org/10.1038/bjc.2013.140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, et al. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. Int J Clin Oncol. 2019;24(5):516–25. https://doi.org/10.1007/s10147-018-01393-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Tang W, Ren L, Liu T, Ye Q, Wei Y, He G, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME Randomized Controlled Trial. J Clin Oncol. 2020;38(27):3175–84. https://doi.org/10.1200/JCO.20.00174This trial was designed for patients with RAS mutant disease and found that the addition of bevacizumab increased the resectability of liver metastases and increased survival compared to chemotherapy alone.

    Article  CAS  PubMed  Google Scholar 

  32. Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–8. https://doi.org/10.1093/annonc/mdu580This study found that in comparison to doublet chemotherapy with bevacizumab, triplet chemotherapy with bevacizumab had superior resection rates and response rates in patients with initially unresectable liver metastases.

    Article  CAS  PubMed  Google Scholar 

  33. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22(9):2042–8. https://doi.org/10.1093/annonc/mdq714.

    Article  CAS  PubMed  Google Scholar 

  34. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. https://doi.org/10.1200/JCO.2012.42.8201.

    Article  CAS  PubMed  Google Scholar 

  35. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85. https://doi.org/10.1016/S1470-2045(13)70154-2.

    Article  CAS  PubMed  Google Scholar 

  36. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508. https://doi.org/10.1016/S1470-2045(15)70127-0.

    Article  CAS  PubMed  Google Scholar 

  37. Cao R, Zhang S, Ma D, Hu L. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol. 2015;32(1):325. https://doi.org/10.1007/s12032-014-0325-9.

    Article  CAS  PubMed  Google Scholar 

  38. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15. https://doi.org/10.1016/S1470-2045(15)00122-9.

    Article  CAS  PubMed  Google Scholar 

  39. Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27(8):1539–46. https://doi.org/10.1093/annonc/mdw206.

    Article  CAS  PubMed  Google Scholar 

  40. Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, et al. A multicenter clinical phase ii study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO Study. Clin Colorectal Cancer. 2018;17(2):147–55. https://doi.org/10.1016/j.clcc.2018.01.011.

    Article  PubMed  Google Scholar 

  41. Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, et al. Phase II randomized trial of sequential or concurrent FOLFOXIRI-bevacizumab versus FOLFOX-bevacizumab for metastatic colorectal cancer (STEAM). Oncologist. 2019;24(7):921–32. https://doi.org/10.1634/theoncologist.2018-0344.

    Article  CAS  PubMed  Google Scholar 

  42. Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, et al. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25(10):2988–95. https://doi.org/10.1158/1078-0432.CCR-18-1221.

    Article  CAS  PubMed  Google Scholar 

  43. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16. https://doi.org/10.1016/S0140-6736(08)60455-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Uetake H, Yasuno M, Ishiguro M, Kameoka S, Shimada Y, Takahashi K, et al. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808). Ann Surg Oncol. 2015;22(3):908–15. https://doi.org/10.1245/s10434-014-4094-7.

    Article  PubMed  Google Scholar 

  45. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235.

    Article  PubMed  Google Scholar 

  46. Terrebonne E, Smith D, Becouarn Y, Michel P, Guimbaud R, Auby D, et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: results of the ETNA cohort study. J Clin Oncol. 2010;28(15_suppl):3594. https://doi.org/10.1200/jco.2010.28.15_suppl.3594.

    Article  Google Scholar 

  47. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26(32):5254–60. https://doi.org/10.1200/JCO.2008.17.7857.

    Article  PubMed  Google Scholar 

  48. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206(1):96–106. https://doi.org/10.1016/j.jamcollsurg.2007.06.290.

    Article  PubMed  Google Scholar 

  49. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26(11):1830–5. https://doi.org/10.1200/JCO.2007.13.7679.

    Article  CAS  PubMed  Google Scholar 

  50. Mahfud M, Breitenstein S, El-Badry AM, Puhan M, Rickenbacher A, Samaras P, et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg. 2010;34(1):92–100. https://doi.org/10.1007/s00268-009-0251-8.

    Article  PubMed  Google Scholar 

  51. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9. https://doi.org/10.1200/JCO.2007.14.9930.

    Article  CAS  PubMed  Google Scholar 

  52. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392–401. https://doi.org/10.1001/jama.2017.7105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705. https://doi.org/10.1200/JCO.2009.27.4860.

    Article  CAS  PubMed  Google Scholar 

  54. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25(5):1018–25. https://doi.org/10.1093/annonc/mdu088.

    Article  CAS  PubMed  Google Scholar 

  55. Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398–411. https://doi.org/10.1016/S1470-2045(19)30798-3This study shows that the perioperative use of cetuximab in patients with resectable or suboptimally resectable colorectal liver metastases confers a significant disadvantage in terms of overall survival.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. https://doi.org/10.1056/NEJMoa0805019.

    Article  PubMed  Google Scholar 

  57. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14. https://doi.org/10.1016/S0140-6736(11)60613-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31(16):1931–8. https://doi.org/10.1200/JCO.2012.44.8308This trial showed that the addition of cetuximab to chemotherapy improved both resectability and survival in patients with initially unresectable KRA wild-type colorectal liver metastases.

    Article  CAS  PubMed  Google Scholar 

  59. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103(10):1542–7. https://doi.org/10.1038/sj.bjc.6605940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschutz A, Wessendorf S, et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019;37(35):3401–11. https://doi.org/10.1200/JCO.19.01340.

    Article  CAS  PubMed  Google Scholar 

  61. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663–71. https://doi.org/10.1200/JCO.2008.20.8397.

    Article  CAS  PubMed  Google Scholar 

  62. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706–13. https://doi.org/10.1200/JCO.2009.27.6055.

    Article  CAS  PubMed  Google Scholar 

  63. Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim KP, et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol. 2013;72(1):223–30. https://doi.org/10.1007/s00280-013-2190-1.

    Article  CAS  PubMed  Google Scholar 

  64. Kohne C, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Cutsem EV. Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): analysis of CRYSTAL and OPUS studies. J Clin Oncol. 2011;29(15_suppl):3576. https://doi.org/10.1200/jco.2011.29.15_suppl.3576.

    Article  Google Scholar 

  65. Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O'Neil BH, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(18_suppl):LBA3. https://doi.org/10.1200/jco.2014.32.18_suppl.lba3.

    Article  Google Scholar 

  66. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. https://doi.org/10.1016/S1470-2045(14)70330-4.

    Article  CAS  PubMed  Google Scholar 

  67. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7. https://doi.org/10.1200/JCO.2013.53.2473.

    Article  CAS  PubMed  Google Scholar 

  68. Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, et al. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). Br J Cancer. 2019;121(3):222–9. https://doi.org/10.1038/s41416-019-0518-2This trial showed that both bevacizumab and cetuximab had similar efficiacy in patients with initially unresectable liver metastases.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Liu Y, Luan L, Wang X. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. Onco Targets Ther. 2015;8:1061–8. https://doi.org/10.2147/OTT.S81442.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80(1):30–6. https://doi.org/10.1093/jnci/80.1.30.

    Article  CAS  PubMed  Google Scholar 

  71. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. https://doi.org/10.1056/NEJMoa032709.

    Article  CAS  PubMed  Google Scholar 

  72. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16. https://doi.org/10.1200/JCO.2008.20.6771.

    Article  CAS  PubMed  Google Scholar 

  73. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31(3):359–64. https://doi.org/10.1200/JCO.2012.44.4711.

    Article  CAS  PubMed  Google Scholar 

  74. Andre T, Vernerey D, Im SA, Bodoky G, Buzzoni R, Reingold S, et al. Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. Ann Oncol. 2020;31(2):246–56. https://doi.org/10.1016/j.annonc.2019.12.006.

    Article  CAS  PubMed  Google Scholar 

  75. Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(11):1543–57. https://doi.org/10.1016/S1470-2045(16)30172-3.

    Article  CAS  PubMed  Google Scholar 

  76. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383–93. https://doi.org/10.1001/jama.2012.385.

    Article  CAS  PubMed  Google Scholar 

  77. Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, et al. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. Ann Oncol. 2017;28(4):824–30. https://doi.org/10.1093/annonc/mdw687.

    Article  CAS  PubMed  Google Scholar 

  78. Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112(12):1921–8. https://doi.org/10.1038/bjc.2015.142.

    Article  CAS  PubMed  Google Scholar 

  79. National Comprehensive Cancer N. Colon Cancer, Version 4.2020. Accessed October 31, 2020.

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Hannah Lu Chang

  2. Division of Hematology/Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Suite U9.436, Dallas, TX, 75390-8584, USA

    Amy Little Jones

Authors
  1. Hannah Lu Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy Little Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy Little Jones.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the topcal of the Topical Collection on Systemic Therapies In Colorectal Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, H.L., Jones, A.L. Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases. Curr Colorectal Cancer Rep 17, 10–22 (2021). https://doi.org/10.1007/s11888-021-00464-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-021-00464-9

Keywords

Search

Navigation